VGF and schizophrenia: As previously reported, proVGF C-terminus plasma levels detected with the same antibody used in this study did not change in the phencyclidine rat models of schizophrenia [22], nor in the plasma of patients with early-stage ALS or in animal models of early motor neuron degeneration, conditions in which other VGF-derived peptides were altered [5, 26, 27].